Business context and reporting period
The supplied filing is Trovagene, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 10, 2016. This does not match the request metadata naming Cardiff Oncology, Inc.; the summary below covers the filing provided. Trovagene was developing and commercializing cell-free DNA diagnostic tests, with a primary focus on urine-based cancer monitoring. Its other areas of interest included infectious disease, transplantation and prenatal genetics.
The company offered laboratory-developed tests through its CLIA-certified, CAP-accredited laboratory. Its tests and platform were still at an early commercial stage, and most reported revenue came from royalties and licensing rather than diagnostic services.
Financial performance and position
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $313,000 | $280,000 |
| Operating expenses | $25.6 million | $15.2 million |
| Operating loss | $25.3 million | $14.9 million |
| Net loss attributable to common stockholders | $27.5 million | $14.3 million |
| Basic loss per share | $1.05 | $0.76 |
| Net cash used in operating activities | $22.1 million | $12.7 million |
| Cash and cash equivalents at year-end | $67.5 million | $27.3 million |
| Working capital at year-end | $60.2 million | $23.2 million |
Revenue increased by $33,000, but remained small relative to spending. FY 2015 revenue included $275,000 in royalties, $14,000 in diagnostic service revenue and $24,000 in other revenue; no license fees were recorded. Cost of revenue was $629,000, exceeding total revenue, and management reported negative gross margins as test volumes and laboratory utilization were being built.
Research and development expense rose 59% to $10.6 million; selling and marketing expense rose 136% to $6.4 million; and general and administrative expense rose 36% to $7.9 million. The company attributed higher R&D costs largely to expanded clinical collaborations and sample processing, and higher commercial spending to salesforce growth and marketing programs. Net interest expense was approximately $1.5 million. A $726,000 loss from the change in fair value of warrant-related derivative liabilities also affected results.
Total debt carrying value was approximately $16.5 million at year-end, comprising $5.2 million current and $11.2 million long-term debt. The company reported $18.8 million of contractual long-term debt obligations including interest. It raised $61.2 million net from common-stock sales during 2015; financing cash flows totaled $64.6 million. Capital expenditures were $2.2 million. Management expected approximately $4.6 million of capital equipment investment in 2016. The company stated that available capital was adequate for the next 12 months, but additional funding would be needed beyond that period absent sufficient operating cash generation.
Material changes versus the prior period
- Net loss attributable to common stockholders nearly doubled, while revenue increased only modestly.
- Operating cash use increased from $12.7 million to $22.1 million, alongside substantial increases in R&D and commercial spending.
- Year-end cash rose by $40.2 million, principally reflecting equity financing, including underwritten offerings in February and July 2015.
- Common shares outstanding increased from 18.9 million to 29.7 million during the year, reflecting financing and option and warrant exercises.
- The company expanded its clinical program and commercial organization, formed the Trovagene Research Institute in Italy, and added urine-based EGFR assays to its commercially available test menu.
Outlook, commentary, risks and unusual items
Management planned to expand clinical evidence and commercial adoption, develop additional mutation assays, pursue reimbursement and continue offering tests as laboratory-developed tests. It also said it expected ongoing operating cash outflows and losses for the foreseeable future; it did not provide a quantified revenue or earnings forecast. Its statement that capital was adequate for the next 12 months was an assessment as of the filing, not a guarantee of future funding.
Key risks include failure to demonstrate clinical utility or secure physician adoption and adequate reimbursement; uncertain regulatory requirements, including possible FDA oversight of laboratory-developed tests; competition from better-resourced diagnostic companies; dependence on clinical collaborators, patient samples and a single San Diego laboratory; and potential dilution or unfavorable financing terms. Debt agreements contain restrictive covenants and collateral provisions. In February 2016, the company signed a term sheet to refinance its existing term loan; the filing describes proposed terms, not a completed refinancing.
Other items to note: the company disclosed potential federal and state tax exposures related to past executive compensation but had recorded no liability; it reported an opposition by an anonymous third party to claims in a European patent; and the CEO received 350,000 immediately vested options in January 2016, with approximately $1.4 million of fair value expected to be expensed in the first quarter of 2016. The company reported no material pending litigation, compliance with debt covenants at year-end, effective disclosure controls and internal control over financial reporting, and an unqualified audit opinion.
Investor verification checklist
- Confirm the issuer: the supplied 10-K is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Assess subsequent filings for actual test volumes, collections, reimbursement, and whether diagnostic revenue began scaling beyond royalties.
- Review updated cash burn, cash runway, capital spending, and any subsequent equity or debt financing and dilution.
- Verify whether the February 2016 debt-refinancing term sheet was completed and review final pricing, covenants, warrants and repayment schedule.
- Evaluate the size, design and outcomes of clinical studies behind management’s performance claims, and distinguish preliminary results from validated clinical utility.
- Check developments in FDA and CLIA oversight, payer coverage and reimbursement, the European patent opposition, and the disclosed executive tax exposure.